6-MAPBT

6-MAPBT, also known as 6-(2-(methylamino)propyl)-1-benzothiophene, is a possible entactogen of the phenethylamine, amphetamine, and benzothiophene families related to MDMA.

It acts as a monoamine releasing agent and serotonin receptor modulator. The drug's EC₅₀Tooltip half-maximal effective concentration values for monoamine release are 57 nM for serotonin and 71 nM for dopamine. It is also a potent agonist of the serotonin 5-HT_1B receptor, with an EC₅₀ of 24 nM, and is a potent antagonist of the serotonin 5-HT_2B receptor, with an IC₅₀Tooltip half-maximal inhibitory concentration of 72 nM. Conversely, it is far weaker as an agonist of the serotonin 5-HT_2A receptor (EC₅₀ = 959 nM) and is inactive at the serotonin 5-HT_1A receptor. In addition to the preceding actions, the drug is a monoamine oxidase A (MAO-A) inhibitor, with an IC₅₀ of 945 nM.

It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents. However, benzothiophenes like 6-MAPBT, despite their induction of dopamine release, are said to lack hyperlocomotion or stimulant-like effects in rodents.

6-MAPBT has been studied and patented by Matthew J. Baggott at Tactogen. The drug has also been patented by Mydecine and given the developmental code name MY300.